Narrow Results

To evaluate the effects of radix Sophorae flavescentis for chronic hepatitis B, a systematic review of randomized clinical trials was conducted. Randomized trials comparing extract of radix Sophorae flavescentis versus placebo, no intervention, non-specific treatment, other active medicines, or interferon for chronic hepatitis B were identified by electronic and manual searches. Trials of Sophorae herb plus other drugs versus other drugs alone were also included. No blinding and language limitations were applied. The methodological quality of trials was assessed by the Jadad scale plus allocation concealment. Meta-analysis was performed where data was available. Twenty-two randomized trials (n = 2409) were included. Methodological quality of the trials was generally low. The combined results showed that matrine (aqueous extract of Sophorae flavescentis) had antiviral activity, positive liver biochemical effects, and improved symptoms and signs compared with non-specific treatment and other herbal medicines. The combination of matrine and interferon-α (IFN-α), thymosin, or basic treatment showed better effects on viral and liver biochemical responses. The antiviral and biochemical responses were not significantly different between matrine and IFN-α. No serious adverse event was reported. Based on the review, Sophorae flavescentis extract (matrine) may have antiviral activity and positive effects on liver biochemistry in chronic hepatitis B. However, the evidence is not sufficient to recommend matrine for routine clinical use due to the generally low methodological quality of the studies. Further rigorous trials are needed.

Experiments were conducted to establish the safety and efficacy of Eucommia ulmoides (Du-Zhong) extract in the treatment of hypertension. Pilot experiments using rats demonstrated that E. ulmoides extract was safe to the saturation limits of the compound. The maximum tolerated dose (MTD) was 1200 mg/kg when administered by gastric gavage at a concentration of 1200 mg/ml. Also, rats given 200 mg/kg, 600 mg/kg or 1200 mg/kg doses of E. ulmoides extract daily for 28 days demonstrated no evidence of acute toxicity as determined by clinical appearance, histopathology and serum chemistry evaluation. Lastly, spontaneous hypertensive rats (SHRs) were administered E. ulmoides extract daily for 22 days. Systolic blood pressure (BP) was measured on treatment days 1, 8, 15 and 22 at 0, 1, 2 and 3 hours post-treatment. Beginning on day 8, E. ulmoides extract administered at the mid or high dosages lowered BP in male, but not female, rats. BP declined at a rate of approximately 10 mmHg per hour. The mid dosage of 600 mg/kg was found to be the minimum effective dose. In conclusion, E. ulmoides extract was non-toxic and effective in reducing systolic BP in the SHR.

AUSTRALIA — Australian Scientist Awarded $1M for Gene Therapy Research.

AUSTRALIA — $900,000 Multiphoton Microscope Unveiled at Sydney's Centenary Institute.

AUSTRALIA — Australian Stem Cell Scientist on Target to Prevent Age-related Loss of Brain Function.

CHINA — Chinese Scientists Complete Successful Greenhouse Breeding of a Medicinal Herb.

CHINA — China Aoxing Pharmaceutical Designated as Key Manufacturer of Cancer Pain Drug, Tilidine.

CHINA — Chinese Neuropsychologist Makes Novel Progress in Studies of Schizophrenia.

JAPAN — Vetter Receives Japanese Certificates of Accreditation of Foreign Manufacturer.

INDIA — Heart Problems to Take Epidemic Form in India.

INDIA — Scientists Discover the Most Important Candidate Genes for Pancreatic Stone Formation.

INDIA — India and Canada to Collaborate on Pharma Opportunities.

INDIA — Tata Drug Development Center Opens in Bangalore.

NEW ZEALAND — A Squid Gel Commands Global Attention.

SINGAPORE — Singapore's National Cancer Center Launches Its First Satellite Clinic.

SINGAPORE — Lien Foundation to Develop Electronic Healthcare System.

TAIWAN — STUT Study Reveals Mushroom Good for Ovarian Cysts.